Top Markets
#1 Orochi Network Orochi Network +73.97%
#2 Bitway Bitway +26.52%
#3 Audiera Audiera +23.90%
#4 RSK Infrastructure Framework RSK Infrastructure Framework +17.56%
#5 Pharos Pharos +16.09%
#6 SOON SOON +14.94%
#7 Taiko Taiko +14.59%
#8 Cheems Token Cheems Token +14.34%
#9 Manadia Manadia +14.25%
#10 Zilliqa Zilliqa +12.53%
Coin of the day
Orochi Network Orochi Network
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Clasificación en acciones #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Precio por acción
$50.95
Capitalización bursátil
$226.41B
Cambio (1 día)
2.58%
Cambio (1 año)
-26.16%
País
DK
Comercio Novo Nordisk A/S (NVO)

Categoría

Healthcare
Ganancias de Novo Nordisk A/S (NVO)
Ganancias en Mar 2026 TTM: $24.72B
Secondo gli ultimi rapporti finanziari di Novo Nordisk A/S, gli utili attuali della società sono $24.72B. Nel 2024, la società ha registrato un utile di $17.75B, un aumento con respecto a agli utili del 2023, che erano di $15.50B. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Novo Nordisk A/S desde 2000 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $24.72B 25.36%
2025 $19.72B 11.11%
2024 $17.75B 14.50%
2023 $15.50B 55.92%
2022 $9.94B 10.02%
2021 $9.03B 3.59%
2020 $8.72B 19.69%
2019 $7.29B -0.35%
2018 $7.31B -6.79%
2017 $7.84B 15.64%
2016 $6.78B 7.06%
2015 $6.34B 14.26%
2014 $5.55B -7.59%
2013 $6.00B 22.00%
2012 $4.92B 28.80%
2011 $3.82B 16.43%
2010 $3.28B 21.42%
2009 $2.70B 13.54%
2008 $2.38B 10.14%
2007 $2.16B 33.54%
2006 $1.62B 24.30%
2005 $1.30B -5.19%
2004 $1.37B 6.85%
2003 $1.28B 44.62%
2002 $888.11M 23.73%
2001 $717.79M 18.82%
2000 $604.10M 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -79.10%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -79.14%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -91.35%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.48B -94.01%
NL
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
ALNY.US
$586.40M -97.63%
US